Embecta Corp. (EMBC) P/E Ratio History
Deep ValueTrading at 2.2x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Embecta Corp. (EMBC) trades at a price-to-earnings ratio of 2.2x, with a stock price of $3.49 and trailing twelve-month earnings per share of $1.90.
The current P/E is 82% below its 5-year average of 12.0x. Over the past five years, EMBC's P/E has ranged from a low of 4.3x to a high of 26.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, EMBC trades at a 91% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, EMBC trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EMBC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
EMBC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
EMBC P/E vs Peers
Consumer health and OTC self-care peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $236M | 21.3 | 6.20 | -12% | |
| $3B | 32.5 | 7.38 | -15% | |
| $4B | 33.7 | - | +5% | |
| $56B | 26.7 | 1.62 | -1% | |
| $213B | 13.7Lowest | 0.66 | +2% | |
| $27B | 33.6 | 3.20 | +47%Best | |
| $11B | 45.5 | 0.44Best | -40% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
EMBC Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $8.84 | $1.22 | 7.2x | -39% |
| FY2026 Q1 | Dec 31 2025 | $11.88 | $2.37 | 5.0x | -58% |
| FY2025 Q4 | - | $14.11 | $1.62 | 8.7x | -27% |
| FY2025 Q3 | Jun 30 2025 | $9.69 | $1.42 | 6.8x | -43% |
| FY2025 Q2 | Mar 31 2025 | $12.75 | $0.89 | 14.4x | +20% |
| FY2025 Q1 | - | $20.65 | $0.99 | 20.9x | +75% |
| FY2024 Q4 | Sep 30 2024 | $14.10 | $1.35 | 10.4x | -13% |
| FY2024 Q3 | Jun 30 2024 | $12.50 | $1.20 | 10.4x | -13% |
| FY2024 Q2 | Mar 31 2024 | $13.27 | $1.21 | 11.0x | -8% |
| FY2024 Q1 | Dec 31 2023 | $18.93 | $0.95 | 19.9x | +66% |
| FY2023 Q4 | Sep 30 2023 | $15.05 | $1.22 | 12.3x | +3% |
| FY2023 Q3 | Jun 30 2023 | $21.60 | $0.82 | 26.3x | +120% |
| FY2023 Q2 | Mar 31 2023 | $28.12 | $1.63 | 17.3x | +44% |
| FY2023 Q1 | Dec 31 2022 | $25.29 | $2.77 | 9.1x | -24% |
| FY2022 Q4 | Sep 30 2022 | $28.79 | $3.88 | 7.4x | -38% |
| FY2022 Q3 | - | $25.32 | $5.88 | 4.3x | -64% |
Average P/E for displayed period: 12.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EMBC — Frequently Asked Questions
Quick answers to the most common questions about buying EMBC stock.
What is EMBC's P/E ratio?
Embecta Corp. (EMBC) trailing twelve-month P/E ratio is 2.2x, based on TTM diluted EPS of $1.90. The 5-year average P/E is 12.0x and the historical range spans 4.3x to 26.3x.
Is EMBC stock overvalued or undervalued?
EMBC trades at 2.2x P/E, below its 5-year average of 12.0x. At the 0th percentile of its historical range (4.3x–26.3x), the stock is priced at a discount to its own history.
Is EMBC stock expensive?
No, EMBC is not expensive on a historical basis. The current P/E of 2.2x is below the 5-year average of 12.0x and sits at the 0th percentile of its valuation range.
What is EMBC's historical P/E range?
Over the past 5 years, EMBC's P/E ratio has ranged from 4.3x to 26.3x, with a median of 10.4x and an average of 12.0x. The current P/E of 2.2x places the stock at the 0th percentile of this range. Full historical data spans 2022–2026.
How does EMBC's P/E compare to the S&P 500?
EMBC trades at 2.2x P/E versus the S&P 500 median of 25.3x. The 91% discount to the market suggests lower growth expectations or perceived higher risk.
How does EMBC's valuation compare to Healthcare peers?
Embecta Corp. P/E of 2.2x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is EMBC's PEG ratio?
EMBC PEG ratio is N/A, based on a P/E of 2.2x and EPS growth of 20.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is EMBC's earnings yield?
EMBC earnings yield is 46.42%, the inverse of its 2.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.